Keep the original finding within reach.
These are the papers and official records linked in the essays, each followed by a note about its role here.
How the hormone message works.
These readings explain the shared biology and some human hormone results. A review joins the ideas together; a study tests a narrower question. Keep an eye on which kind you’re reading.
- GHRH and its analogues in health and disease
Granata and colleagues, 2025. Explains the hormone family and how its signals connect.
- Sermorelin's childhood diagnostic and treatment uses
Prakash and Goa, 1999. Covers the former childhood uses and reported reactions to sermorelin.
- CJC-1295's lasting GH and IGF-1 response
Teichman and colleagues, 2006. Small healthy-adult studies of the DAC form, measuring hormones and safety.
- GHRH(1-29) and hormone levels in older men
Corpas and colleagues, 1992. Healthy older men took part in this short study of hormone changes.
The next shelf covers changes measured in particular groups of people.
What changed, and for whom.
A childhood growth finding belongs with the children studied. A result about fat distribution belongs with its adult participants. Those details help keep a useful finding from becoming a much wider claim.
- Growth in children with a GH shortage
Thorner and colleagues, 1996. Faster average first-year growth in prepubertal children with GH deficiency; no placebo group.
- Tesamorelin and visceral fat in adults with HIV
Falutz and colleagues, 2007. Adults who had HIV and excess abdominal fat received tesamorelin or placebo for 26 weeks.
- EGRIFTA WR (tesamorelin) prescribing information
DailyMed. The approved use, trial follow-up and warnings, including the limits of long-term safety knowledge.
The official records answer a different set of questions.
Approvals, safety concerns and access.
These records explain a product’s history or legal status. A withdrawn approval and a withdrawn compounding nomination mean different things. The records below help untangle them.
- Withdrawal of the former Geref approvals
Federal Register, 2009. Ends the former sermorelin approvals; current preparations don’t inherit them.
- FDA's later determination on Geref
Federal Register, 2013. Separates Geref’s departure from questions of safety and effectiveness. It gives no new product an approval.
- FDA's assessment of the CJC-1295 forms
FDA, 2024. Reviews the different forms, the limited human evidence and safety concerns.
- FDA's safety concerns and withdrawn nominations
FDA. The page’s date is April 22, 2026. CJC-1295 appears among withdrawn nominations, alongside safety concerns.
- FDA's tesamorelin application record
Drugs@FDA. Records tesamorelin’s status as a biologic, which has a different legal pathway.
- What FDA says about compounded medicines
FDA. Explains compounding, the lack of approval for compounded medicines and why biologics don’t qualify for the drug-compounding exemptions.
- Licensure and a patient's location
HHS. Explains how a patient’s location matters for a telehealth professional’s authority to practise.
When checking a sentence, read it beside the source it links to.
There’s room to read further.
The sources support the research and regulatory discussion here. They don’t assess a reader. The sermorelin service invitation is explained on the prescribing page; it isn’t a study of treatment benefit.